Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.PMID:38527096 | DOI:10.1093/oncolo/oyae036 (Source: The Oncologist)
Source: The Oncologist - March 25, 2024 Category: Cancer & Oncology Authors: William J Phillips Fred Saad Jennifer Leigh Alborz Jooya Colleen Webber Scott Morgan Robert MacRae Jean-Marc Bourque Peter Tanuseputro Michael Ong Source Type: research
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
CONCLUSION: CUP exhibits poor prognosis with limited benefits from standard treatment regimens. A significant proportion of CUPs carry actionable alterations, underscoring the importance of genomic profiling to gather additional treatment opportunities. In addition, immunotherapy might represent a valuable treatment option for a subset of CUP. Finally, accurate definition of sequencing methods and platforms is crucial to overcome NGS failures.PMID:38520742 | DOI:10.1093/oncolo/oyae038 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Luca Boscolo Bielo Carmen Belli Edoardo Crimini Matteo Repetto Liliana Ascione Gloria Pellizzari Celeste Santoro Valeria Fuorivia Massimo Barberis Nicola Fusco Elena Guerini Rocco Giuseppe Curigliano Source Type: research
Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
Oncologist. 2024 Mar 23:oyae046. doi: 10.1093/oncolo/oyae046. Online ahead of print.ABSTRACTThymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing i...
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Christopher S Nabel Jeanne B Ackman Yin P Hung Abner Louissaint Gregory J Riely Source Type: research
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW. Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study. The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.PMID:38520745 | DOI:10.1093/oncolo/oyae043 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Giulia Pasello Martina Lorenzi Daniela Scattolin Alessandro Del Conte Fabiana Cecere Alberto Pavan Marianna Macerelli Valentina Polo Sara Pilotto Mariacarmela Santarpia Enrico Cumerlato Valentina Da Ros Giada Targato Alberto Bortolami Laura Bonanno Alessa Source Type: research
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology
CONCLUSION: CUP exhibits poor prognosis with limited benefits from standard treatment regimens. A significant proportion of CUPs carry actionable alterations, underscoring the importance of genomic profiling to gather additional treatment opportunities. In addition, immunotherapy might represent a valuable treatment option for a subset of CUP. Finally, accurate definition of sequencing methods and platforms is crucial to overcome NGS failures.PMID:38520742 | DOI:10.1093/oncolo/oyae038 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Luca Boscolo Bielo Carmen Belli Edoardo Crimini Matteo Repetto Liliana Ascione Gloria Pellizzari Celeste Santoro Valeria Fuorivia Massimo Barberis Nicola Fusco Elena Guerini Rocco Giuseppe Curigliano Source Type: research
Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors
Oncologist. 2024 Mar 23:oyae046. doi: 10.1093/oncolo/oyae046. Online ahead of print.ABSTRACTThymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing i...
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Christopher S Nabel Jeanne B Ackman Yin P Hung Abner Louissaint Gregory J Riely Source Type: research
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World
CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW. Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study. The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.PMID:38520745 | DOI:10.1093/oncolo/oyae043 (Source: The Oncologist)
Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Giulia Pasello Martina Lorenzi Daniela Scattolin Alessandro Del Conte Fabiana Cecere Alberto Pavan Marianna Macerelli Valentina Polo Sara Pilotto Mariacarmela Santarpia Enrico Cumerlato Valentina Da Ros Giada Targato Alberto Bortolami Laura Bonanno Alessa Source Type: research
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review
CONCLUSION: Our research emphasizes the importance of evaluating the gonadal axis before treatment in patients considered at risk and testing it at regular intervals or in case of clinical suspicion.PMID:38518107 | DOI:10.1093/oncolo/oyae024 (Source: The Oncologist)
Source: The Oncologist - March 22, 2024 Category: Cancer & Oncology Authors: Giacomo Massa Luca Zambelli Ernesto Zecca Morena Shkodra Gabriele Tin è Augusto Caraceni Source Type: research
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review
CONCLUSION: Our research emphasizes the importance of evaluating the gonadal axis before treatment in patients considered at risk and testing it at regular intervals or in case of clinical suspicion.PMID:38518107 | DOI:10.1093/oncolo/oyae024 (Source: The Oncologist)
Source: The Oncologist - March 22, 2024 Category: Cancer & Oncology Authors: Giacomo Massa Luca Zambelli Ernesto Zecca Morena Shkodra Gabriele Tin è Augusto Caraceni Source Type: research
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Oncologist. 2024 Mar 18:oyae042. doi: 10.1093/oncolo/oyae042. Online ahead of print.NO ABSTRACTPMID:38498045 | DOI:10.1093/oncolo/oyae042 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Tito Fojo Meredith LaRose Susan E Bates Source Type: research
Renaming Palliative Cancer Therapies: Call It What It Is
Oncologist. 2024 Mar 18:oyae039. doi: 10.1093/oncolo/oyae039. Online ahead of print.NO ABSTRACTPMID:38498046 | DOI:10.1093/oncolo/oyae039 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Kimberly E Kopecky Toby C Campbell Source Type: research
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Oncologist. 2024 Mar 18:oyae053. doi: 10.1093/oncolo/oyae053. Online ahead of print.NO ABSTRACTPMID:38498842 | DOI:10.1093/oncolo/oyae053 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Source Type: research
The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype
Oncologist. 2024 Mar 18:oyae042. doi: 10.1093/oncolo/oyae042. Online ahead of print.NO ABSTRACTPMID:38498045 | DOI:10.1093/oncolo/oyae042 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Tito Fojo Meredith LaRose Susan E Bates Source Type: research
Renaming Palliative Cancer Therapies: Call It What It Is
Oncologist. 2024 Mar 18:oyae039. doi: 10.1093/oncolo/oyae039. Online ahead of print.NO ABSTRACTPMID:38498046 | DOI:10.1093/oncolo/oyae039 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Authors: Kimberly E Kopecky Toby C Campbell Source Type: research
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
Oncologist. 2024 Mar 18:oyae053. doi: 10.1093/oncolo/oyae053. Online ahead of print.NO ABSTRACTPMID:38498842 | DOI:10.1093/oncolo/oyae053 (Source: The Oncologist)
Source: The Oncologist - March 18, 2024 Category: Cancer & Oncology Source Type: research
